Comparative Pharmacology
Head-to-head clinical analysis: NEUPOGEN versus RELEUKO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEUPOGEN versus RELEUKO.
NEUPOGEN vs RELEUKO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. It acts by binding to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and maturation of neutrophils.
Recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates proliferation, differentiation, and activation of neutrophil progenitor cells.
5 mcg/kg subcutaneously or intravenously once daily for up to 14 days, or until absolute neutrophil count reaches 10,000/mm³ after nadir. For mobilization of peripheral blood progenitor cells: 10 mcg/kg subcutaneously once daily for 6-7 days.
5 mcg/kg subcutaneously once daily for up to 10 days or until neutrophil count >10,000/mcL after nadir.
None Documented
None Documented
3.5 hours (range 2.5–4.5 hours) in healthy subjects; terminal elimination half-life is prolonged in patients receiving chemotherapy due to decreased clearance, approximately 5.5 hours.
Terminal half-life approximately 5.3 hours (range 4.5–6.2 hours) in adults with normal renal function.
Primarily renal; greater than 90% of filgrastim is eliminated via renal excretion as intact protein and degraded metabolites. Biliary/fecal excretion is minimal (<1%).
Primarily renal (approximately 70% as intact drug). Minor biliary/fecal elimination (<5%).
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor